Diomics Announces Agreement With Department of Defense to Accelerate Development and Testing of Diocheck™ SARS-CoV-2 Immune Response Indicator Patch
Excerpt from the Press Release:
SAN DIEGO–(BUSINESS WIRE)–Diomics, a San Diego-based biotech company, today announced that it has been awarded a $2,125,000 Medical Technology Enterprise Consortium (MTEC) Other Transaction Agreement (OTA) with the U.S. Department of Defense to accelerate development and testing of its Diocheck™ SARS-CoV-2 Visual Immune Response Indicator, a transdermal skin patch that monitors and reports when the wearer’s body has mounted an immune response to SARS-CoV-2, the virus that causes COVID-19.
A change in skin color visible through the patch indicates that the person has either recently been exposed to the virus and should get tested and quarantine, or has recovered from a previous coronavirus infection and may still retain immunity. The patch begins to detect an immune response within 24 to 36 hours of application and is expected to effectively monitor for up to 14 days.
Click the button below to continue reading the Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?